Fernandez-Banet, Julio

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 1,304

The BioMart community portal: an innovative alternative to large, centralized data repositories

Smedley, D., Haider, S., Durinck, S., Pandini, L., Provero, P., Allen, J., Arnaiz, O., Awedh, M. H., Baldock, R., Barbiera, G., et al. (2015) · Nucleic Acids Research

Bioinformatics and Genomic NetworksScientific Computing and Data Management

Cited by 755

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 553

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Briere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 168

Abstract LB-C09: the KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

Briere, D. M., Calinisan, A., Aranda, R., Sudhakar, N., Hargis, L., Gatto, S., Fernandez-Banet, J., Pavlicek, A., Engstrom, L. D., Hallin, J., et al. (2019) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 13